Search results for "ADCs"

Article ADC Development Robust Despite Lackluster Performance
The target for ADCs has primarily been cancer, and the cytotoxic agents that are used in ADCs are typically more potent than currently used anti-cancer drugs (1). The ADC construct combines a t…

Article Tackling Analytical Method Development for ADCs
Fortunately, both improvements in analytical technology and increased experience with ADCs are leading to improved strategies for analytical method development and validation. Both small and large…

Article Extractables Studies for Single‑Use Systems Used in ADC Manufacturing
Single‑use (SU) systems have great potential in antibody‑drug conjugates (ADC) manufacturing. The use of organic solvents in the ADC process might , however, raise questions about potential leac…

Article Witnessing Major Growth in Next-Generation Antibodies
The global market for next-generation antibodies, including antibody drug conjugates (ADCs), engineered antibodies, bispecific antibodies, antibody fragments, antibody-like proteins and biosimilar ant…

Article Being Thorough When Transferring Technology
BioPharm: Are there specific challenges for the tech transfer of antibody-drug conjugates (ADCs)? Monoclonal antibodies? Cell therapies? Moscariello and Young (CMC Biologics): The major challenges…

Article Nurturing Knowledge from Disparate Data Streams
Anderson points to antibody-drug conjugates (ADCs) as an example. “ADCs comprise an antibody, a small-molecule cytotoxic payload, and a linker of some kind, which can be an oligomer or other small to …

Article The Challenge of Disruptive Technologies in Bioprocessing
The industry pipeline is growing in complexity to include emerging molecules such as bispecific antibodies, antibodydrug conjugates (ADCs), and those viral vectors for gene and cell therapies. Some of…

Article Aseptic Processing: Keeping it Safe
Concerns related to operator safety exist when dealing with highly potent or cytotoxic drugs, such as is the case with the manufacture of antibody drug conjugates (ADCs) with cytotoxic payloads. To pr…

Article Addressing the Challenges in Downstream Processing Today and Tomorrow
ANTIBODY-DRUG CONJUGATES Numerous antibody drug conjugates (ADCs) are in clinical trials with most of them being used in cancer treatment with a toxin payload (26). The major downstream challenge …

Article Exploring the world of antibodies: mAbs, Fabs, dAbs, and bsAbs
There is a vast array of antibody variants, including multispecific (msAb), bispecific antibodies (bsAb), antibody fragments (Fab, dAb, scFv), and antibody-drug conjugates (ADC). But with this…

Next Page